The idea that mental disorders are caused by a biological mechanism is linked with prolonged use of antidepressants and ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.

Metastasis-directed stereotactic radiotherapy alongside biological cancer therapy appears safe, new data show.

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

A major American medical device manufacturer is investing $110 million to expand production in Nebraska as part of an effort ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Pregnant women who take biologic medication for rheumatoid arthritis are not running the risk of their infant developing serious/opportunistic infections, according to research presented at the 2017 ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while secukinumab, ...

Rystiggo (rozanolixizumab) is a brand-name subcutaneous infusion that’s prescribed for myasthenia gravis. Rystiggo has interactions with some other drugs. Examples include immunoglobulins and ...